Strategic partnerships NRx has a defense-oriented subsidiary and a collaboration with Zeta Surgical to develop Combined Neuroplastic Therapy, creating sales opportunities in military, first-responder, and government sectors for CNS treatments and rapid deployment therapies.

Clinical progress Active development of NRX-101 a fixed dose DCS+lurasidone therapy with NMDA platform positioning, including a pivotal trial and FDA-cleared path for combination with robotic-enabled Transcranial Magnetic Stimulation, signaling near-term adoption potential in mental health care settings.

Expansion potential Engagement with DARPA for contract negotiations on SPARC-TMS clinical trial indicates readiness for large-scale, technology-enabled CNS interventions in defense and austere environments.

Financial readiness Strong funding profile with substantial growth capital and revenue scale in the tens of millions, suggesting capacity to scale pilots, regulatory activities, and early market access initiatives with risk-managed investments.

Market positioning Focused on unmet needs in suicidal depression, PTSD, and related CNS disorders using NMDA-based therapies, presenting a differentiated value proposition for specialty pharma distributors, contract research organizations, and health systems seeking innovative mood disorder treatments.